Merck & Co Inc (MRK)

MRK (NYSE:Drugs)
$59.08
neg -0.58
-0.97%
Today's Range: 59.01 - 59.81 | MRK Avg Daily Volume: 10,514,100
Last Update: 11/24/14 - 3:26 PM EST
Volume: 5,162,031
YTD Performance: 19.20%
Open: $59.51
Previous Close: $59.66
52 Week Range: $47.61 - $61.33
Oustanding Shares: 2,850,873,371
Market Cap: 169,284,860,770
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 6 6 7 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.08 2.00
Latest Dividend: 0.44
Latest Dividend Yield: 2.96%
Dividend Ex-Date: 09/11/14
Price Earnings Ratio: 32.27
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
32.27 32.50 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.38% 22.71% 74.75%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.80 -0.04 -0.01
Net Income -28.30 3.60 0.65
EPS -26.70 4.32 0.74
Earnings for MRK:
EBITDA 14.65B
Revenue 44.03B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.86 $0.78 $3.49 $3.58
Number of Analysts 8 1 12 12
High Estimate $0.88 $0.78 $3.51 $3.75
Low Estimate $0.83 $0.78 $3.46 $3.26
Prior Year $0.88 $0.88 $3.49 $3.49
Growth Rate (Year over Year) -1.99% -11.36% 0.02% 2.58%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Buy Gilead Sciences Real Money Pro($)

Its prospects exploded with a breakthrough drug.
Bullish
Nov 18, 2014 | 7:22 AM EST
MRK estimates were raised through 2017, Morgan Stanley said. Company can deliver higher Vytorin/Zetia sales. Equal-weight rating and ne...
The U.S. markets and economy are unique.
Beat the short-term crown in these three areas for the long term.

This Morning's Market Setup Real Money Pro($)

Where it began.
Market action could get a bumpy after last week's big move.
Americans are living much longer these days -- and there are a number of ways to invest.

The Fibocall: Merck Real Money Pro($)

Look to be a small buyer now that shares triggered a long-term oversold signal.
Buying this dip may be harder than you think.
Stop picking on PepsiCo, Allergan and Apple.

Columnist Conversations

D.R. Horton has been on a tear since the October lows. Just before the major market bottom on the 15th D...
Mixed day in the market with the NASDAQ being the strongest of the three main indices. Apple (AAPL) being a c...
Lang:
Today is rollup day -- just a week ago I mentioned here we bought some SNDK Jan 100 calls at 2.82. In my note...
Hardwood flooring and home improvement specialist Lumber Liquidators (LL) bottomed out at $47.76 in October am...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.